Background Lenvatinib is a multitargeted tyrosine kinase inhibitor approved for treating
patients with locally recurrent or metastatic progressive radioiodine-refractory differentiated …

Surgical treatment of advanced thyroid malignancy can be morbid, compromising normal
functions of the upper aerodigestive tract. There is a paucity of guidelines dedicated to the …

Background: Surgery is the primary treatment for locally advanced thyroid cancer. For some
cases, R0/R1 resection could not be achieved at initial diagnosis and neoadjuvant treatment …

Background Surgery is the primary treatment for locally advanced differentiated thyroid
cancer (DTC). However, some locally advanced patients are not candidates for R0/1 …

A 73-year-old female presenting with haemoptysis and dyspnoea was found to have a
locally advanced left thyroid mass and vocal cord palsy. A CT scan of the neck and thorax …

Interventions: Apatinib (500 mg orally once a day) was initially used to treat this patient as a
neoadjuvant therapy. Outcomes: Six weeks later, the tumor dramatically shrunk from 56× 37 …

Background: Papillary thyroid carcinoma (PTC) is the most common and less aggressive
thyroid cancer, but some patients may display locally advanced disease. Therapeutic …

Background Locally infiltrating (T4) differentiated thyroid carcinomas (DTC) represent a
challenge. Surgical strategy and adjuvant therapy should be planned balancing morbidity …

Neoadjuvant lenvatinib for inoperable thyroid cancer: A case report and literature review - PMC
Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

Introduction Locally advanced thyroid cancer refers to thyroid cancer that invades important
structures of the neck, with poor prognosis. Neoadjuvant targeted therapy has the potential …